Sai Life Sciences hit a new high of Rs 1,578, gaining 4% intraday and 8% in two days, with Jefferies noting its beat was driven by 24% YoY CRO growth and margin gains. Jefferies said management cited strong RFP inflows from Big Pharma, 90% plus of targeted FY27 revenue already covered by orders, an expected 40:60 H1:H2 revenue split versus 48:52 last year implying 20% plus sales growth, a dedicated peptide development lab coming online shortly and a Greenfield peptide manufacturing facility planned for FY28, while maintaining a Buy rating with target of Rs 1,610.